THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCE

Author:

Kalfas Stefanie,Visvanathan KumarORCID,Chan KimORCID,Drago JohnORCID

Abstract

ABSTRACTIntroductionIvermectin is a commonly used antihelminthic agent with over 35 years of established safety data in humans. Recent data demonstrates antiviral activity in vitro against SARS-CoV-2, in addition to a range of viruses. In vitro and animal models also provide evidence of immunomodulatory action. These additional modes of action are supported by in silico modelling, which propose a number of viral and host targets that would mediate these effects.ObjectivesThe aim of this study is to systematically review the published and preprint clinical literature and study results that assessed the potential role of ivermectin as a COVID-19 therapeutic and prophylactic agent.MethodsWe conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov, Global Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International Clinical Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and references from relevant articles.ResultsSearch keywords- “COVID-19 (and synonyms) AND ivermectin”- generated 86 articles on PubMed, 48 on medRvix and 37 on clinicaltrials.gov at the time of writing. Twelve of these were listed as completed clinical trials and of these, 8 were included as investigators had released results. Positive mortality benefit, reduced time to clinical recovery, reduced incidence of disease progression and decreased duration of hospital admission were reported in patients across all stages of clinical severity.LimitationsDue to the time-critical nature of the COVID-19 pandemic our review included preprint data, which must be interpreted with caution while it awaits peer review.

Publisher

Cold Spring Harbor Laboratory

Reference62 articles.

1. World Health Organization Coronavirus disease 2019 (COVID–19) Weekly epidemiological update 24 August, 2020. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports (accessed August 29 2020).

2. The World Bank. The Global Economic Outlook During the COVID–19 Pandemic: A Changed World. 2020. https://www.worldbank.org/en/news/feature/2020/06/08/the–global–economic–outlook–during–the–covid–19–pandemic–a–changed–world (accessed August 31 2020).

3. Pastor–Barriuso R , Perez–Gomez B , Hernan MA , et al. SARS–CoV–2 infection fatality risk in a nationwide seroepidemiological study. medRxiv 2020: 2020.08.06.20169722.

4. The FDA–approved drug ivermectin inhibits the replication of SARS–CoV–2 in vitro;Antiviral Res,2020

5. Campbell WC , Burg RW , Fisher MH , Dybas RA . The Discovery of Ivermectin and Other Avermectins. In: Magee PS , Kohn GK , Menn JJ , eds. Pesticide synthesis through rational approaches. Washington, DC: American Chemical Society; 1984: 5– 20.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3